Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Fossil Inc. (FOSL - Analyst Report) has authorized a new share buyback program to repurchase up to $1.0 billion of its outstanding shares, reflecting the company’s strong balance sheet and robust cash flow. The program will expire on December 31, 2016 but can be discontinued at any time on the company’s discretion. The company had repurchased approximately 9 million shares for $693 million on December 4 under its current $750 million share repurchase program. The company expects to complete the $750 million program in the first quarter of 2013.
Fossil recently reported its third quarter 2012 earnings of $1.28 per share, which exceeded the year-ago earnings by 17.4% and the Zacks Consensus Estimate by 9.4%. The results also exceeded management’s guidance range of $1.15–$1.17 per share. The upswing in results was driven by top-line growth, improved margins and prudent expense management.
Fossil’s net sales during the quarter increased 6.4% to $684.2 million, driven by strong global watch sales and improved leather businesses. The acquisition of the Skagen brand also fuelled sales growth. The jewelry and eye-wear businesses partially offset sales growth. Net sales, however, lagged the Zacks Consensus Estimate of $715 million. The company lowered its net sales guidance for the fourth quarter 2012 due to expectation of a decline in European wholesale businesses. Fossil expects sales to increase approximately 12% in contrast to 16% growth forecasted previously. On a constant currency basis, the company expects net sales to increase 13% compared with 18% forecasted previously.
Adjusted earnings (excluding non-recurring costs associated with the acquisition of Skagen as well as certain tax benefits) for the fourth quarter are expected in the range of $2.26 – $2.29 per share. For fiscal 2012, Fossil has raised its adjusted earnings per share guidance to a range of $5.42 to $5.45 compared with the previous range of $5.29 to $5.34.
The Zacks Consensus Estimate is pegged at $2.27 and $5.40 per share for the fourth quarter and fiscal year 2012, respectively.
We have a Neutral recommendation on the stock over the long term. Currently, Fossil carries a Zacks #2 Rank (short-term Buy rating) in contrast to its peer Guess? Inc. (GES - Analyst Report), which carries a Zacks #3 Rank (short-term Hold rating).
Get the full Analyst Report on GES - FREE
Get the full Analyst Report on FOSL - FREE